CN105451754A - 在关节病的情况下胃酶抑素的关节内施用 - Google Patents

在关节病的情况下胃酶抑素的关节内施用 Download PDF

Info

Publication number
CN105451754A
CN105451754A CN201480044142.6A CN201480044142A CN105451754A CN 105451754 A CN105451754 A CN 105451754A CN 201480044142 A CN201480044142 A CN 201480044142A CN 105451754 A CN105451754 A CN 105451754A
Authority
CN
China
Prior art keywords
pepstatin
cathepsin
intra
arthrosis
intraarticular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480044142.6A
Other languages
English (en)
Chinese (zh)
Inventor
M·克莱恩
R·沃德皮亚
H·居林
S·林德曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CN105451754A publication Critical patent/CN105451754A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480044142.6A 2013-08-06 2014-07-07 在关节病的情况下胃酶抑素的关节内施用 Pending CN105451754A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13003923 2013-08-06
EP13003923.3 2013-08-06
PCT/EP2014/001861 WO2015018472A1 (de) 2013-08-06 2014-07-07 Intraartikuläre applikation von pepstatin bei arthrose

Publications (1)

Publication Number Publication Date
CN105451754A true CN105451754A (zh) 2016-03-30

Family

ID=48948200

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480044142.6A Pending CN105451754A (zh) 2013-08-06 2014-07-07 在关节病的情况下胃酶抑素的关节内施用

Country Status (9)

Country Link
US (2) US9750784B2 (https=)
EP (1) EP3030250B1 (https=)
JP (1) JP6336067B2 (https=)
CN (1) CN105451754A (https=)
AU (1) AU2014304950B2 (https=)
CA (1) CA2920420C (https=)
ES (1) ES2759060T3 (https=)
IL (1) IL243983B (https=)
WO (1) WO2015018472A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7541746B2 (ja) * 2019-05-21 2024-08-29 国立大学法人 東京大学 脳腫瘍の検出用蛍光プローブ

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3906085A (en) * 1973-05-21 1975-09-16 Lilly Co Eli Determination of hypertension associated with elevated renin levels
WO2012107153A1 (de) * 2011-02-08 2012-08-16 Merck Patent Gmbh Aminostatin-derivate zur behandlung von arthrose

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1286846C (en) 1985-02-12 1991-07-23 Catherine Cazaubon Peptide derivatives which inhibit renin and acid proteases
US6251928B1 (en) 1994-03-16 2001-06-26 Eli Lilly And Company Treatment of alzheimer's disease employing inhibitors of cathepsin D
CA2280096A1 (en) 1997-02-04 1998-08-06 The Regents Of The University Of California Nanomolar, non-peptide inhibitors of cathepsin d
US5962506A (en) 1997-07-07 1999-10-05 Pharmacopeia, Inc. Glycol and hydroxyphosphonate peptidomimetics as inhibitors of aspartyl proteases
US5986102A (en) 1998-04-29 1999-11-16 Pharmacopeia, Inc. Hydroxypropylamide peptidomimetics as inhibitors of aspartyl proteases
JP2000300266A (ja) * 1999-04-20 2000-10-31 St Marianna Univ School Of Medicine ポリペプチド及びｄｎａ
US7132568B2 (en) 2002-06-17 2006-11-07 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
ES2323068T3 (es) 2003-08-08 2009-07-06 Schering Corporation Inhibidores de bace-1 de aminas ciclicas con un sustituyente de benzamida.
EP1654380A4 (en) * 2003-08-14 2009-09-09 Insight Biopharmaceuticals Ltd METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING HEPARANASE ACTIVATION AND USES THEREOF
GB0325830D0 (en) 2003-11-05 2003-12-10 Novartis Ag Organic compounds
JP2007528404A (ja) 2004-03-09 2007-10-11 エラン ファーマシューティカルズ，インコーポレイテッド 置換された尿素およびカルバメート、フェナシル−２−ヒドロキシ−３−ジアミノアルカン、ならびにベンズアミド−２−ヒドロキシ−３−ジアミノアルカン系のアスパラギン酸プロテアーゼ阻害薬
US20050239836A1 (en) 2004-03-09 2005-10-27 Varghese John Substituted hydroxyethylamine aspartyl protease inhibitors
US20080132477A1 (en) 2005-01-13 2008-06-05 Claudia Betschart Macrocyclic Compounds Useful as Bace Inhibitors
CA2609562A1 (en) 2005-06-14 2006-12-28 Schering Corporation Macrocyclic heterocyclic aspartyl protease inhibitors
EP1745778A3 (en) 2005-07-20 2007-03-07 Speedel Experimenta AG Diaminoalcohols as therapeutic compounds
EP1745776A1 (en) 2005-07-20 2007-01-24 Speedel Experimenta AG Aminoalcohols as therapeutic compounds
EP1745777A1 (en) 2005-07-20 2007-01-24 Speedel Experimenta AG Amido-aminoalcohols as therapeutic compounds
GB0526614D0 (en) 2005-12-30 2006-02-08 Novartis Ag Organic compounds
EP1872780A3 (en) 2006-06-14 2008-04-30 Speedel Experimenta AG Omega-Phenyloctanamides as therapeutic compounds
EP1867329A3 (en) 2006-06-14 2008-05-07 Speedel Experimenta AG 5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonanamides as therapeutic compounds
EP1987834A3 (en) 2007-02-13 2008-11-19 Speedel Experimenta AG Substituted piperidines as therapeutic compounds
WO2008119772A1 (en) 2007-03-30 2008-10-09 Medivir Ab Amide derivatives as inhibitors of aspartyl proteases
WO2009013293A1 (en) 2007-07-24 2009-01-29 Novartis Ag Substituted cyclohexanecarboxamides useful as bace inhibitors
US20150225369A1 (en) * 2012-08-29 2015-08-13 Merck Patent Gmbh Ddr2 inhibitors for the treatment of osteoarthritis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3906085A (en) * 1973-05-21 1975-09-16 Lilly Co Eli Determination of hypertension associated with elevated renin levels
WO2012107153A1 (de) * 2011-02-08 2012-08-16 Merck Patent Gmbh Aminostatin-derivate zur behandlung von arthrose

Also Published As

Publication number Publication date
EP3030250B1 (de) 2019-08-28
AU2014304950A1 (en) 2016-03-17
US20170348380A1 (en) 2017-12-07
JP6336067B2 (ja) 2018-06-06
WO2015018472A1 (de) 2015-02-12
JP2016527284A (ja) 2016-09-08
AU2014304950B2 (en) 2019-09-12
EP3030250A1 (de) 2016-06-15
IL243983B (en) 2020-04-30
IL243983A0 (en) 2016-04-21
US20160175381A1 (en) 2016-06-23
US9750784B2 (en) 2017-09-05
ES2759060T3 (es) 2020-05-07
CA2920420C (en) 2021-11-23
CA2920420A1 (en) 2015-02-12

Similar Documents

Publication Publication Date Title
US20250302818A1 (en) Topical formulations comprising montelukast and combinations with mussel adhesive proteins
US12129313B2 (en) Anti-inflammatory use of peptide
US20230348536A1 (en) Conjugates of montelukast and peptides
US20220001014A1 (en) Compositions and methods for inducing biological mimicry in a mammal for the prevention and/or treatment of covid-19 and other diseases
JP2006508971A (ja) プロテアーゼ阻害剤を使用して炎症性疾患を治療する組成物及び方法
KR20210016365A (ko) 새로운 약제학적 용도
RU2542449C2 (ru) Композиции и способы лечения рака мочевого пузыря
WO2017101748A1 (en) Short synthetic peptide and uses thereof
CN105451754A (zh) 在关节病的情况下胃酶抑素的关节内施用
KR102852789B1 (ko) NF-κB 억제제의 엑소솜 기반 전달의 사용
WO2005072528A1 (en) Anticancer glycoside compounds
CN103370331B (zh) 用于治疗关节病的氨基他汀衍生物
CN116322671A (zh) 皮肤病学病症的治疗
CN104507957B (zh) 用于治疗关节病的羟基他汀衍生物
TWI913236B (zh) 新多功能寡肽
US20200109170A1 (en) Short synthetic peptide and uses thereof
CN118236380A (zh) 盐酸布那唑嗪在防治肠缺血再灌注损伤中的应用
US20130064878A1 (en) Wound healing compositions and methods
HK40033390A (en) Conjugates of montelukast and peptides

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20160330

RJ01 Rejection of invention patent application after publication